Thijs van Haaps/LinkedIn
Oct 29, 2025, 07:38
Thijs van Haaps and Team Show That Andexanet Alfa May Go Beyond Apixaban and Rivaroxaban
RPTH Journal shared a post on LinkedIn:
“New in RPTH!
Thijs van Haaps and team show that Andexanet alfa may go beyond apixaban and rivaroxaban—showing reversal potential for enoxaparin. In both healthy volunteers and bleeding patients, anti-Xa activity fell rapidly and 88% achieved good hemostasis.”
Title: Andexanet Alfa for the Reversal of the Low-Molecular-Weight Heparin Enoxaparin
Authors: Thijs F. van Haaps, Alexander P. Benz, Lizhen Xu, Saskia Middeldorp, John W. Eikelboom, Truman J. Milling, Jr., Mark Crowther, Lisa Holer, Stephan Nolan, Per Ladenvall, Genmin Lu, Michiel Coppens
Read more here.
Stay updated with Hemostasis Today.
-
Mar 18, 2026, 16:34Richard Buka: Exploring the COBRRA Trial in the Latest Episode of Don’t Just Read the Abstract
-
Mar 18, 2026, 16:22Heghine Khachatryan: Navigating the New Era of Hemophilia Gene Therapy
-
Mar 18, 2026, 16:21Georges Chahoud: Top Take-Home Messages from the AHA/ACC/Multisociety Acute PE Guideline
-
Mar 18, 2026, 16:19Cedric Hermans: Unleashing the Potential of Physical Activity in Hemophilia A Patients
-
Mar 18, 2026, 16:17Asif Mushtaq: Managing Cardiac Surgery with Cardiopulmonary Bypass in Hemophilia
-
Mar 18, 2026, 16:15Amir Kraitzer: Engineering Hemocompatible Surfaces to Overcome Thrombosis in Medical Devices
-
Mar 18, 2026, 16:11Hemant Sharma: Advancing Neonatal Care with New Strategies to Prevent IVH
-
Mar 18, 2026, 16:09Yves Bikorimana: How a Simple Temperature Change Can Trigger Antibody-Mediated Destruction of RBCs
-
Mar 18, 2026, 16:07Scott Isaacs: Optimizing Brain Vitality and Slowing Neurodegeneration Through Daily Habits